Implication des calpaïnes lors d'un remodelage musculaire induit par un traitement chronique au clenbutérol

Autor: Douillard, Aymeric

Afin de lutter efficacement contre les malversations du dopage, il apparaît essentiel de comprendre les mécanismes conduisant au remodelage musculaire. Dans ce but nous avons analysé les effets d’un β2-agoniste, le clenbutérol, sur le remodela

Externí odkaz: http://www.theses.fr/2011MON14001/document

A multicenter randomized controlled trial of a 3-L/kg/min versus 2-L/kg/min high-flow nasal cannula flow rate in young infants with severe viral bronchiolitis (TRAMONTANE 2)

Autor: Milesi, Christophe, PIERRE, Anne-Florence, DEHO, Anna, POUYAU, Robin, Liet, Jean-Michel, Guillot, Camille, GUILBERT, Anne-Sophie, Rambaud, Jérôme, MILLET, Astrid, Afanetti, Mickael, GUICHOUX, Julie, GENUINI, Mathieu, MANSIR, Thierry, Bergounioux, Jean, Michel, Fabrice, Marcoux, Marie-Odile, Baleine, Julien, Durand, Sabine, Durand, Philippe, Dauger, Stéphane, Javouhey, Etienne, Leteurtre, Stéphane, Brissaud, Olivier, Renolleau, Sylvain, PORTEFAIX, Aurélie, Douillard, Aymeric, Cambonie, Gilles, FOR THE GFRUP RESPIRATORY STUDY GROUP, for the GFRUP Respiratory Study Group

Publikováno v: Intensive Care Medicine
Intensive Care Medicine, Springer Verlag, 2018, 44 (11), pp. 1870-1878. ⟨10.1007/s00134-018-5343-1⟩

High-flow nasal cannula (HFNC) therapy is increasingly proposed as first-line respiratory support for infants with acute viral bronchiolitis (AVB). Most teams use 2 L/kg/min, but no study compared different flow rates in this setting. We hypothesized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f3335da9df7b12e89619c6f1946087e
https://pubmed.ncbi.nlm.nih.gov/30483835

Calpastatin overexpression in the skeletal muscle of mice prevents clenbuterol-induced muscle hypertrophy and phenotypic shift.

Autor: Douillard, Aymeric¹, Galbes, Olivier¹, Begue, Gwenaelle¹, Rossano, Bernadette¹, Levin, John¹, Vernus, Barbara¹, Bonnieu, Anne¹, Candau, Robin¹, Py, Guillaume¹

Publikováno v: Clinical & Experimental Pharmacology & Physiology. Apr2012, Vol. 39 Issue 4, p364-372. 9p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinical Characteristics and Risk Factors of Extensive Macular Atrophy with Pseudodrusen: The EMAP Case-Control National Clinical Trial

Autor: Douillard, Aymeric, Picot, Marie-Christine, Delcourt, Cecile, Lacroux, Annie, Zanlonghi, Xavier, Puech, Bernard, Defoort-Dhelemmes, Sabine, Drumare, Isabelle, Jozefowicz, Elsa, Bocquet, Beatrice, Baudoin, Corinne, Marzouka, Nour Al-Dain, Perez-Roustit, Sarah, Arsene, Sophie, Gissot, Valerie, Devin, Francois, Arndt, Carl, Wolff, Benjamin, Mauget-Faysse, Martine, Quaranta, Maddalena, Mura, Thibault, Deplanque, Dominique, Oubraham, Hassiba, Cohen, Salomon Yves, Gastaud, Pierre, Zambrowsky, Olivia, Creuzot Garcher, Catherine, Said, Saddek Mohand, Garavito, Rocio Blanco, Souied, Eric, Sahel, José-Alain, Audo, Isabelle, Hamel, Christian, Meunier, Isabelle

Publikováno v: Ophthalmology: Journal of The American Academy of Ophthalmology
Ophthalmology: Journal of The American Academy of Ophthalmology, Elsevier, 2016, 123 (9), pp.1865-1873. 〈10.1016/j.ophtha.2016.05.018〉
Ophthalmology: Journal of The American Academy of Ophthalmology, Elsevier, 2016, 123 (9), pp.1865-1873. ⟨10.1016/j.ophtha.2016.05.018⟩
Ophthalmology: Journal of The American Academy of Ophthalmology, 2016, 123 (9), pp.1865-1873. ⟨10.1016/j.ophtha.2016.05.018⟩

Purpose: To assess the association of clinical and biological factors with extensive macular atrophy with pseudodrusen (EMAP) characterized by bilateral macular atrophy occurring in patients aged 50 to 60 years and a rapid progression to legal blindn

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b01d04ce19a76424fabf0e4267649c27
https://pubmed.ncbi.nlm.nih.gov/27320518